Overview

Phase ll Study of HEC585 in Patients With IPF

Status:
Recruiting
Trial end date:
2023-05-11
Target enrollment:
Participant gender:
Summary
A Phase ll Study to evaluate the efficacy and safety of various doses of HEC585 Tablets in patients with idiopathic pulmonary fibrosis
Phase:
Phase 2
Details
Lead Sponsor:
Sunshine Lake Pharma Co., Ltd.
Treatments:
Pirfenidone